Numerous tyrosine kinase inhibitors (TKIs) with Hsp90 inhibition activity exert their actions by inhibiting cancer cells in the G1/S and G2/M cell cycle phases, and upregulation of p53. Here, HSP90AA1 is linked to cancer.